Weekly Spotlight - 27.11.24

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!

Latest News

Tiziana Secures Funding for Small Clinical Trial of Intranasal Foralumab for ALS Treatment

Tiziana Therapeutics has secured funding for a small clinical trial to test the safety and efficacy of intranasal foralumab, a potential treatment for ALS. The trial aims to deliver the drug directly to the brain, bypassing traditional oral or intravenous routes, which could offer new hope for ALS patients.

New iPSC Repository Accelerates ALS Research with Expanded Cell Lines

A new repository of induced pluripotent stem cells (iPSCs) is accelerating ALS research by providing scientists with a valuable resource to study the disease. This repository allows for more precise and personalized studies, potentially leading to better understanding and treatment of ALS.

FDA Grants Orphan Drug Status to RAG21 for ALS Treatment

The FDA has given orphan drug designation to RAG21, a potential treatment for ALS. This designation helps speed up the development and review process for drugs that treat rare diseases, offering hope for new treatments for ALS patients.

Neurosense Therapeutics to Join 2024 International Symposium on ALS/MND Research and Advances

Neurosense Therapeutics will participate in the 2024 International Symposium on ALS/MND, presenting updates on their therapeutic approaches and research aimed at treating ALS. The symposium brings together experts to share advancements and discuss future directions in ALS research and treatment.